Background. Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered
in South Africa (SA) to reduce the risk of stroke and systemic embolism in patients with atrial …

Objectives Dabigatran has a better safety profile and requires less monitoring, but is costlier
than warfarin. This study evaluated the cost-utility of dabigatran relative to warfarin for …

Objectives The introduction of new oral anticoagulants for the prevention of stroke in atrial
fibrillation (AF) has changed the clinical management of AF. To inform decision making …

Objective: To estimate the economic implications of introducing dabigatran etexilate
('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial …

Background Economic evaluation of dabigatran, a new anti-antithrombotic agent, is done
mostly in Western countries. It remains to be seen whether dabigatran will be cost effective …

Objective: To assess the cost-effectiveness of dabigatran etexilate ('dabigatran') vs vitamin K
antagonists (VKAs) in the Belgian healthcare setting for the prevention of stroke and …

This article provides an overview of the clinical profile of oral dabigatran etexilate
(Pradaxa®, Pradax™)[hereafter referred to as dabigatran] when used for the prevention of …

Background To compare the management cost and cost‐effectiveness of dabigatran with
warfarin in patients with nonvalvular atrial fibrillation (AF) from the hospital's and patients' …

Dabigatran etexilate is a newly approved agent for prophylaxis of stroke in atrial fibrillation.
Through narrative review, the authors assess evidence of the efficacy of dabigatran in stroke …

Aims Patients with atrial fibrillation have a significantly increased risk of thromboembolic
events such as ischaemic stroke, and patients are therefore recommended to be treated with …